查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1541648

2024-2032 年按疫苗類型（減毒、去活化、基於亞單位、基於類毒素、基於DNA）、工作流程（下游、上游）、應用（人用、獸用）和地區分類的疫苗合約製造市場報告

Vaccine Contract Manufacturing Market Report by Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), Workflow (Downstream, Upstream), Application (Human Use, Veterinary), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球疫苗合約製造市場規模達28億美元。

疫苗合約製造是指將疫苗的大規模生產外包給合約製造組織（CMO）。這些組織提供眾多服務，包括製劑前工作、製劑開發、方法開發、穩定性研究、臨床前活動、註冊批次和商業生產。除此之外，他們還提供專業知識和創新技術來擴大製藥公司的生產鏈。目前，由於開發成本降低和生產方案複雜，全球範圍內對外包疫苗生產活動的需求正在增加。

疫苗接種在改善人類和獸醫健康方面發揮關鍵作用。它減少了對抗生素的需求並預防疾病。人們對疫苗接種和許多相關益處（例如預防嚴重疾病和傳染病）的認知不斷提高，正在刺激對免疫計劃和接種的需求。這與對生產資本要求的複雜性的了解相結合，導致領先的製藥公司將疫苗生產外包。除此之外，資源匱乏國家缺乏疫苗生產設備和熟練勞動力也促進了全球疫苗合約製造市場的成長。此外，技術進步，包括引入 EB66 和 GPEx 等表達系統以及細胞培養基平台，正在支持市場成長。此外，許多國家的冠狀病毒病 (COVID-19) 病例數量驚人成長，促使疫苗開發商與 CMO 簽署外包協議。這為市場的成長創造了有利的前景。

本報告回答的關鍵問題：

  • 迄今為止，全球疫苗合約製造市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球疫苗合約製造市場有何影響？
  • 主要區域市場有哪些？
  • 根據疫苗類型，市場的詳細情形如何？
  • 基於工作流程的市場區隔是怎樣的？
  • 基於應用的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球疫苗合約製造市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球疫苗合約製造市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依疫苗類型

  • 減弱的
    • 市場趨勢
    • 市場預測
  • 去活化
    • 市場趨勢
    • 市場預測
  • 基於亞基
    • 市場趨勢
    • 市場預測
  • 基於類毒素
    • 市場趨勢
    • 市場預測
  • 基於DNA
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依工作流程

  • 下游
    • 市場趨勢
    • 關鍵環節
      • 填充和完成操作
      • 分析和品質控制研究
      • 包裝
    • 市場預測
  • 上游
    • 市場趨勢
    • 關鍵環節
      • 哺乳動物表達系統
      • 細菌表現系統
      • 酵母表現系統
      • 桿狀病毒/昆蟲表現系統
      • 其他
    • 市場預測

第 8 章：市場區隔：按應用

  • 人類使用
    • 市場趨勢
    • 市場預測
  • 獸醫
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Ajinomoto Co. Inc.
    • Albany Molecular Research Inc
    • Catalent Inc
    • Cobra Biologics Limited (Charles River Laboratories International Inc.)
    • Cytovance Biologics Inc. (Hepalink USA Inc.)
    • Fujifilm Holdings Corporation
    • ICON plc
    • IDT Biologika GmbH
    • Lonza Group AG
    • Merck KGaA
    • Pharmaceutical Product Development LLC
    • PRA Health Sciences Inc.
Product Code: SR112024A3872

The global vaccine contract manufacturing market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 8.8% during 2024-2032.

Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.

Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on vaccine type, workflow and application.

Breakup by Vaccine Type:

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Breakup by Workflow:

Downstream

Fill and Finish Operations

Analytical and QC Studies

Packaging

Upstream

Mammalian Expression Systems

Bacterial Expression Systems

Yeast Expression Systems

Baculovirus/Insect Expression Systems

Others

Breakup by Application:

Human Use

Veterinary

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.

Key Questions Answered in This Report:

  • How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global vaccine contract manufacturing market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the workflow?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global vaccine contract manufacturing market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Attenuated
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subunit-based
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Toxoid-based
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 DNA-based
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Workflow

  • 7.1 Downstream
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Fill and Finish Operations
      • 7.1.2.2 Analytical and QC studies
      • 7.1.2.3 Packaging
    • 7.1.3 Market Forecast
  • 7.2 Upstream
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Mammalian Expression Systems
      • 7.2.2.2 Bacterial Expression Systems
      • 7.2.2.3 Yeast Expression Systems
      • 7.2.2.4 Baculovirus/Insect Expression Systems
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Human Use
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Veterinary
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ajinomoto Co. Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Albany Molecular Research Inc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Catalent Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Fujifilm Holdings Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICON plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IDT Biologika GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lonza Group AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pharmaceutical Product Development LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 PRA Health Sciences Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Vaccine Contract Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2023
  • Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
  • Figure 76: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
  • Figure 77: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Contract Manufacturing Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Workflow (in Million US$), 2024-2032
  • Table 4: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Vaccine Contract Manufacturing Market: Competitive Structure
  • Table 7: Global: Vaccine Contract Manufacturing Market: Key Players